Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Epstein-Barr virus (EBV) is associated with various neoplasms.
• EBV nuclear antigen 1 (EBNA1) expression is a common feature in EBV-associated cancers.
• Targeted gene therapy offers a potential treatment strategy for these malignancies.

Purpose of the Study:

• To investigate the efficacy of a targeted suicide gene therapy system for EBV-associated neoplasms.
• To utilize EBV-based plasmid vectors and hemagglutinating virus of Japan (HVJ)-liposomes for targeted delivery.
• To assess the selective killing of cancer cells expressing EBNA1.

Main Methods:

• Development of EBV-based plasmid vectors containing a marker gene and EBV replication origin (oriP).
• Transduction of leukemic cell lines with the vector system.
• Introduction of the herpes simplex virus (HSV)-1 thymidine kinase (Tk) gene for suicide gene therapy.
• Treatment with ganciclovir (GCV) to induce cell death in transduced cells.

Main Results:

• The marker gene was exclusively detected in cells expressing EBNA1, confirming targeted transduction.
• Transduction with the HSV-1 Tk gene led to a significant reduction in viable cell number.
• This reduction was specific to EBNA1-positive cells when treated with ganciclovir (GCV).

Conclusions:

• The developed virus-free system demonstrates targeted gene delivery and selective cancer cell killing.
• This approach shows promise for the gene therapy of EBV-associated neoplasms.
• Further research may validate this system for clinical applications in treating EBV-driven cancers.